Transferrin-scFv Anti-VEGF Fusion for Blood-Retina Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering anti-VEGF antibodies and fusion proteins are limited by requiring painful intravitreal injections and have side effects and high costs of treatment; they also present improved anticancer activity by binding to cancer cell surface that has over-expressed transferrin receptors and enters the cancer cells more efficiently.
Innovation Solution
The RNAT82 is a humanized monoclonal single-chain variable fragment (scFv) that binds and inhibits vascular endothelial growth factor A (VEGF-A), decreasing neovascularization in the eye. Thus, it can treat Neovascular Age-related Macular Degeneration (nAMD, wet AMD, or wAMD) and Diabetic Macular Edema (DME). The exact mechanism can help reduce the growth of cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF antibodies are administered by intravitreal injection, then therapeutic effect is achieved, but treatment is painful and has severe side effects
Solution Approach 1:
The patent uses transferrin as an intermediary carrier to deliver the anti-VEGF scFv antibody. The transferrin-scFv fusion protein exploits the transferrin receptor-mediated transcytosis pathway to cross the blood-retina barrier, avoiding direct intravitreal injection. This intermediary approach enables systemic administration while achieving ocular therapeutic effect, thereby eliminating injection pain and reducing side effects.
2Ease of operation
If anti-VEGF antibodies are converted to single chain variable fragments and conjugated with transferrin, then alternate administration route is enabled, but manufacturing complexity increases
Solution Approach 1:
The patent merges the anti-VEGF scFv antibody with transferrin to create a single fusion protein molecule. This combining approach enables the therapeutic agent to utilize the natural transferrin receptor pathway for blood-retina barrier crossing, allowing systemic administration without requiring separate delivery mechanisms or complex manufacturing processes for combining separate components.
3Reliability
If RNAT82 binds to transferrin receptors on cancer cells, then anticancer activity is improved, but specificity requirements increase
Solution Approach 1:
The patent exploits the cancer cells' own overexpressed transferrin receptors to deliver the therapeutic agent. Since many cancer cells naturally overexpress transferrin receptors due to their high metabolic demands, the RNAT82 fusion protein automatically targets these cells more efficiently through receptor-mediated endocytosis. This self-service mechanism enhances anticancer activity while the natural biology of cancer cells provides the necessary specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAT82 can be manufactured using standard recombinant technology or delivered in vivo through mRNA. The RNAT82 can be administered intravenously, subcutaneously, or intramuscularly. The number of protein molecules generated from a single mRNA is primarily determined by “translation efficiency.” The stability of the mRNA molecule, the availability of different translation components, and the existence of translation initiation sites are some factors affecting translation efficiency.
Implementation Method 1
conjugating them with transferrin protein... binding to cancer cell surface that has over-expressed transferrin receptors and enters the cancer cells more efficiently
Implementation Method 2
Anti-VEGF antibodies and fusion proteins target and inhibit VEGF... These antibodies bind to VEGF molecules, preventing them from interacting with their receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells
Data Source
AI summary
Anti-VEGF (Vascular Endothelial Growth Factor) (RNAT82) is a single chain variable fusion protein comprising fragment antibody variable light and variable heavy chains with binding domains conjugated with transferrin protein to induce transcytosis across the blood-retina barrier to treat neovascular (wet) age-related macular degeneration (AMD) by systemic administration instead of intravitreal administration, and binding and transcytosis to cancer cells to treat cancer. The present invention can be manufactured by recombinant process or by encoding in vivo as mRNA.